Seres Therapeutics (MCRB) news
Recent news
Seres Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on January 13, 2023, that its Compensation and Talent Committee granted inducement equity awards to five new employees on January 11, 2023. The awards included stock options to purchase 9,000 shares of common stock and 4,500 restricted stock units…
AInvest Wire · Sep 8, 2026Seres says it swung to H1 net loss of 1.7 bln yuan
AInvest Wire · Aug 19, 2026Seres Therapeutics - on July 31, entered agreement to terminate lease early with BMR-Sidney Research Campus LLC, reducing facilities costs
AInvest Wire · Aug 4, 2026Seres Therapeutics, Inc.: H.C. Wainwright initiates coverage with buy rating and target price $12
AInvest Wire · Jun 23, 2026Seres Therapeutics - Nestlé Health Science to pay Seres $25 mln in 2026 for Vowst milestone buy-out
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced that it will receive a $25 million installment payment from Nestlé Health Science in 2026, contingent on fulfilling transition obligations related to the sale of its VOWST business. This payment is part of a broader agreement under which Seres…
AInvest Wire · Jun 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.